ITMCTR2000002926尚未招募1 期
To evaluate the dose-effect relation and efficacy by using chuanxiongchatiaosan, comprised of the different processed products of the rhizome of chuanxiong to treat the wind-attacking-type migraine
Beijing University of Chinese Medicine Third affiliated Hospital0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 70(—)
- 性别
- All
入选标准
- •1. Patients are 18 to 70 years of age with a diagnosis of migraine according to western and TCM criteria, and had experienced 2 times per month in the past 3 months;
- •2. No preventive drugs were used before the attack, and no other traditional Chinese medicine or western medicine was used during the attack;
- •3. All patients participating to the clinical trial are voluntary and provide the written informed consent.
排除标准
- •1. Pregnant or nursing women;
- •2. Patients do not conform to the diagnosis of migraine according to the western and TCM criteria;
- •3. Patients suffer from other diseases, such as heart, liver, kidney, hematopoietic system and other serious primary diseases, cancers or mental diseases;
- •4. Headache is one of the symptoms of other diseases, such as hypertension, post-traumatic brain syndrome and organic lesions in the brain, poisoning, or systemic disease;
- •5. Preventive drugs were used before the attack, or other traditional Chinese medicine or western medicine was used during the attack.
研究者
相似试验
已完成
3 期
Dose Response Study of a Complementary Medicine Formulation in Primary HypercholesterolaemiaACTRN12605000232639Pathways40
招募中
2 期
Stem cell treatment for COVID-19COVID-19.COVID-19 diseaseU07.01IRCT20200421047150N1DEY Company90
已完成
不适用
A study to investigate the efficacy and dose response of Euglena by questionnaires for a measure of the subjective well-beingHealthy individualsJPRN-UMIN000037200everage Brain Inc.210
进行中(未招募)
不适用
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular GoiterEUCTR2005-004451-35-NLGenzyme Europe BV99
进行中(未招募)
不适用
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiter - NDMultinodular goiterMedDRA version: 6.1Level: PTClassification code 10018498EUCTR2005-004451-35-ITGenzyme Europe BV99
